Intactis Bio Corp.

Intactis Bio Corp. , based in the US, offers innovative biocomputation solutions that integrate neural tissue with silicon technology, overcoming the challenges faced by conventional AI and ML systems. Founded in 2024 and headquartered in Salt Lake City, US, Intactis Bio Corp. specializes in advanced biocomputational solutions.

They have completed a total of 1 deal, with their most recent funding round occurring on May 19, 2026. The company does not have publicly listed subsidiaries or parent companies. Intactis Bio’s primary offering is its large-scale neural tissue biocomputer, designed to address the limitations of silicon-based artificial intelligence (AI) and machine learning (ML) systems. This innovative solution combines silicon computing with living neurons, enabling efficient computation.

It features a proprietary neural tissue and brain-machine interface that allows for complex calculations while maintaining long-term viability for centimeter-scale tissues. The biocomputer targets energy-constrained data centers, facilitating the operation of AI/ML models and high-performance workloads without the typical power constraints of traditional computing. Intactis Bio aims to penetrate markets in North America and Europe, forming partnerships with research institutions, biotechnology firms, and data-centric companies. Intactis Bio generates revenue through subsidized AI/ML services linked to their biocomputation platform.

Clients benefit from expert data analysis solutions, including a promotional offering of complimentary analysis with their biocomputation services. Their transactional model emphasizes partnerships and collaborations, primarily operating within a B2B framework. These partnerships often involve established research institutions and biotech companies seeking to integrate Intactis Bio's technology into their processes. The company is positioned to deliver customized solutions tailored to the specific processing needs of clients, aligning strategically with their technological requirements.

Revenue streams are expected to grow as Intactis Bio pursues further investment and develops its innovative offerings in biotechnology and AI sectors. Intactis Bio Corp. plans to launch upcoming products aimed at enhancing their biocomputation capabilities, with specific details on release dates yet to be disclosed. The company is focused on expanding into new markets in North America and Europe, with particular emphasis on partnerships with research institutions and biotechnology firms by the end of 2026.

The recent venture funding raised in May 2026 from Nucleus Capital and rpv will support these initiatives, fostering growth in their product development and market reach.